Form 4: Veracyte Director Thomas F. Miller Awarded Restricted Stock Units

Veracyte, Inc. Director Thomas F. Miller has been granted 9,321 restricted stock units (RSUs) as part of his compensation, aligning his interests with shareholders.

Summary

• Thomas F. Miller, a Director of Veracyte, Inc. (VCYT), was awarded 9,321 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 18, 2025.
• The RSUs were acquired at a price of $0 per unit, indicating a grant rather than a purchase.
• Following this transaction, Mr. Miller beneficially owns a total of 25,828 shares of Common Stock.
• The awarded RSUs are scheduled to vest in full on the first anniversary of the grant date (June 18, 2026) or immediately prior to the Company's next annual meeting of stockholders, whichever occurs earlier.
• Additionally, the restricted stock units will vest in full immediately in the event of a change in control of Veracyte, Inc.

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates continued alignment of a director's interests with the company's performance through equity compensation, which is a healthy governance practice.

Positives

• The grant of restricted stock units to Director Thomas F. Miller aligns his financial interests directly with those of the company's shareholders, incentivizing long-term performance and value creation.
• Equity compensation is a standard practice for retaining and motivating key personnel, including directors.

Risks

• The restricted stock units are subject to vesting conditions; if these conditions (time-based or change of control) are not met, the RSUs may be forfeited.
• The value of the vested RSUs is dependent on the future market price of Veracyte, Inc. common stock, exposing the director to market fluctuations.

Future Outlook

The awarded restricted stock units are set to vest on the first anniversary of the grant date (June 18, 2026) or earlier, immediately prior to the company's next annual meeting of stockholders, or upon a change in control of the Issuer.

Industry Context

This transaction represents a routine equity compensation grant to a director, a common practice across various industries, particularly in the biotechnology and diagnostics sectors where long-term incentives are used to align leadership with company growth and innovation.

Comparison to Industry Standards

• The grant of restricted stock units to directors is a widely accepted and common form of non-cash compensation in publicly traded companies across industries, including healthcare and biotechnology.
• The vesting schedule, which includes time-based vesting and accelerated vesting upon a change of control, is typical for RSU awards to senior leadership and board members, similar to practices observed at companies like Exact Sciences Corp. (EXAS) or Guardant Health, Inc. (GH).

Corporate Governance

Related Party Transactions

• The grant of restricted stock units to Thomas F. Miller, a Director of Veracyte, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's incentives with shareholder interests, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The restricted stock units will vest on June 18, 2026, or earlier, based on the specified vesting conditions.

Key Dates

Keywords

Veracyte, VCYT, SEC Form 4, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Insider Transaction, Beneficial Ownership, Corporate Governance